These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 25819692

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
    Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC.
    Lancet; 2015 Jun 13; 385(9985):2355-62. PubMed ID: 25819691
    [Abstract] [Full Text] [Related]

  • 3. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.
    Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Goker-Alpan O, Watman N, El-Beshlawy A, Kishnani PS, Pedroso ML, Gaemers SJM, Tayag R, Peterschmitt MJ.
    Blood; 2017 Apr 27; 129(17):2375-2383. PubMed ID: 28167660
    [Abstract] [Full Text] [Related]

  • 4. Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy.
    Zimran A, Goldblatt J, Szer J.
    Blood Cells Mol Dis; 2018 Feb 27; 68():14-16. PubMed ID: 28935503
    [No Abstract] [Full Text] [Related]

  • 5. Gaucher disease and its treatment options.
    Bennett LL, Mohan D.
    Ann Pharmacother; 2013 Sep 27; 47(9):1182-93. PubMed ID: 24259734
    [Abstract] [Full Text] [Related]

  • 6. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States.
    Balwani M, Burrow TA, Charrow J, Goker-Alpan O, Kaplan P, Kishnani PS, Mistry P, Ruskin J, Weinreb N.
    Mol Genet Metab; 2016 Feb 27; 117(2):95-103. PubMed ID: 26387627
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
    Mistry PK, Lukina E, Ben Turkia H, Shankar SP, Baris H, Ghosn M, Mehta A, Packman S, Pastores G, Petakov M, Assouline S, Balwani M, Danda S, Hadjiev E, Ortega A, Gaemers SJM, Tayag R, Peterschmitt MJ.
    Am J Hematol; 2017 Nov 27; 92(11):1170-1176. PubMed ID: 28762527
    [Abstract] [Full Text] [Related]

  • 9. Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1.
    Cox TM, Charrow J, Lukina E, Mistry PK, Foster MC, Peterschmitt MJ.
    Genet Med; 2023 Feb 27; 25(2):100329. PubMed ID: 36469032
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.
    Belmatoug N, Di Rocco M, Fraga C, Giraldo P, Hughes D, Lukina E, Maison-Blanche P, Merkel M, Niederau C, Plӧckinger U, Richter J, Stulnig TM, Vom Dahl S, Cox TM.
    Eur J Intern Med; 2017 Jan 27; 37():25-32. PubMed ID: 27522145
    [Abstract] [Full Text] [Related]

  • 12. [Molecular basis of treatment in Gaucher's disease].
    Pocoví M.
    Med Clin (Barc); 2011 Sep 27; 137 Suppl 1():32-8. PubMed ID: 22230123
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Enzyme replacement therapy decreases hypergammaglobulinemia in Gaucher's disease.
    Deibener J, Kaminsky P, Jacob C, Dousset B, Klein M, Duc M.
    Haematologica; 1998 May 27; 83(5):479-80. PubMed ID: 9658738
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Clinical outcomes of 2 pediatric patients with Gaucher's disease in enzyme replacement therapy for 9 years].
    Quijada Fraile P, Martín Hernández E, Teresa García-Silva M.
    Med Clin (Barc); 2011 Sep 27; 137 Suppl 1():43-5. PubMed ID: 22230125
    [Abstract] [Full Text] [Related]

  • 17. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
    Canda E, Kose M, Kagnici M, Ucar SK, Sozmen EY, Coker M.
    Blood Cells Mol Dis; 2018 Feb 27; 68():180-184. PubMed ID: 28111116
    [No Abstract] [Full Text] [Related]

  • 18. Enzyme-replacement therapy for Gaucher's disease.
    N Engl J Med; 1991 Dec 19; 325(25):1809-11. PubMed ID: 1944489
    [No Abstract] [Full Text] [Related]

  • 19. Enzyme replacement therapy in Gaucher's disease.
    Kasturi L, Amin SA.
    Indian Pediatr; 2001 Jun 19; 38(6):686-8. PubMed ID: 11418745
    [No Abstract] [Full Text] [Related]

  • 20. Neurological features in Gaucher's disease during enzyme replacement therapy.
    Ono H, Fujiwara M, Ito K, Ueda H, Mizoguchi N, Sakura N.
    Acta Paediatr; 2001 Feb 19; 90(2):229-31. PubMed ID: 11236058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.